murine B cell line J2-44 cells were kindly provided by Dr. Henry H. Wortis (Tufts University, Boston, Mass., USA) and maintained in RPMI 1640 medium (Invitrogen) supplemented with 10% heatinactivated FCS, 100 U/ml penicillin, 100 g/ml streptomycin, 2 m M glutamine and 50 M 2-mercaptoethanol. HEK293 cells expressing mTLR4/MD2-CD14 were obtained from Invivogen (San Diego, Calif., USA) and maintained in the same medium with Plat-E with 50 g/ml of hygromycin B instead of puromycin.
Isolation of Splenic B Cells
Splenic B cells were isolated from mouse spleens by negative selection using MACS mouse B cell isolation kit (Miltenyi Biotech, Auburn, Calif., USA) or EasySep (StemCell Technologies, Vancouver, B.C., Canada). The purity of isolated B cells was assessed by the staining of isolated cells with anti-mouse CD19 mAb (1D3; BD Biosciences, San Jose, Calif., USA) and was more than 94% throughout this study.
B Cell Proliferation Assay
Purified B cells were suspended at 1.0 ! 10 7 cells/ml in Hank's balanced salt solution (Invitrogen) containing 3% heat-inactivated FCS and 4-6 M of carboxyfluorescein diacetate succinimidyl ester (Invitrogen) for 7 min at 25 ° C. Carboxyfluorescein succinimidyl ester (CFSE)-labeled B cells were added in 96-well flat-bottom plate at 2.0 ! 10 5 cells/well in the 200 l of RPMI medium (Invitrogen) supplemented with 10% heat-inactivated FCS, 2 m M glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 1 m M nonessential amino acid, 1 m M sodium pyruvate and 50 M 2-melcaptoethanol. For the BCR stimulation, goat F(ab ) 2 antimouse IgM (Jackson Immunoresearch, West Grove, Pa., USA) was added to each well. For TLR stimulation, poly(I:C), LPS and CpG1826 (Invivogen) were added. All culture was done with triplicate samples. The cells were allowed to proliferate for 2-3 days. Cells were then harvested and analyzed by flow cytometry with the exclusion of dead cells using 1 g/ml of propidium iodide staining. More than 2.5 ! 10 4 total counts were acquired in FACS Caliber (BD Biosciences) and analyzed with Flowjo (Tree Star, San Carlos, Calif., USA). For the experiment using immobilized antibodies, 96-well ELISA plate was first coated with 20 g/ml of neutravidin (Pierce, Rockford, Ill., USA), then washed with phosphate-buffered saline (PBS) and added with biotinylated anti-CD22 (Cy34.1; BD Biosciences) or mouse IgG1 isotype-matched control antibody (Biolegend, San Diego, Calif., USA). Then wells were washed with PBS and added with B cells in the presence of LPS, CpG or anti-IgM. To count the living cell number, 1.0 ! 10 4 of Calibrite beads (BD Biosciences) was added to each well before harvesting cells. The living cell number was calculated by the formula: living cells number in the well = the number of living cells acquired ! the number of beads acquired / 1.0 ! 10 4 .
Activation Marker Expression Analysis
Purified B cells or J2-44 cells were cultured for 2 days with or without stimuli as described above. Cells were then harvested, washed with Hank's balanced salt solution containing 0.1% BSA, 1 m M MgSO 4 , 1.3 m M CaCl 2 and 0.1% NaN 3 (FACS buffer). Cells were then blocked with anti-mouse CD16/32 (2.4G2; BD Biosciences), and stained with anti-CD86 (GL1; eBiosicence, San Diego, Calif., USA) and MHC class II I-A b (AF6-120.1; BD Biosciences). The stained cells were washed with FACS buffer and analyzed by flow cytometry as described above.
TLR9 Expression Analysis
Purified B cells were fixed with 3% parafolmaldehyde in PBS for 10 min at 25 ° C. Then cells were permeabilized with PBS containing 0.1% saponin (Sigma-Aldrich, St. Louis, Mo., USA), 1% BSA and 0.05% NaN 3 (PBS-S). Fixed and permeabilized cells were blocked with 1% normal rat serum in PBS-S and stained with anti-TLR9 Ab (IMG-431; Imgenex, San Diego, Calif., USA) followed by phycoerythrin-labeled goat F(ab ) 2 anti-rabbit IgG (Southern Biotech, Birmingham, Ala., USA). The stained cells were washed with PBS-S and analyzed by flow cytometry.
Real-Time PCR
Total RNA was isolated from WT and Cd22 -/-B cells with TRIzol reagent (Invitrogen). Random hexamer-primed firststrand cDNA was synthesized from DNase-treated total RNA by reverse transcription using Superscript III (Invitrogen). SYBR Green-based real-time PCR was performed using the DyNAmo SYBR Green qPCR Kit (Finnzymes Oy, Espoo, Finland). Signals were normalized to ␤ -actin and normalized data were used to quantitate relative levels of TLR3 and 4 by using ⌬ ⌬ Ct analysis. Primers used were below: 5 -atgatacagggattgcaccc-3 and 5 -atagggacaaaagtccccca-3 for TLR3, 5 -ttcacctctgccttcactaca-3 and 5 -gggacttctcaaccttctcaa-3 for TLR4, 5 -ccgtgggtcgcgagaac-3 and 5 -aactcaggtagtcacggagtaccg-3 for SOCS1, 5 -tcccatgcc-gctcacag-3 and 5 -acaggaccagttccaggtaattg for SOCS3 [14] , and 5 -tgggacgacatggagaagatctggc-3 and 5 -tacgaccagaggcatacagggacagc-3 for ␤ -actin.
Transduction of the J2-44 Cell Line with Murine CD22
cDNA for murine CD22 was subcloned into the pMXs-IG vector. The CD22-pMXs-IG vector and the translation-incompatible CD3 -pMXs-IG vector were used for transduction of the J2-44 cell line to establish CD22/J2-44 cells and Mock/J2-44 cells, respectively. Briefly, the retrovirus packaging cell line Plat-E were transfected with the pMXs-IG vectors by Lipofectamin2000 ( Invitrogen). After 2 days, the culture supernatant was harvested and added to J2-44 cells with 8 g/ml of Polybrane (Millipore, Bedford, Mass., USA). J2-44 cells expressing EGFP were sorted to more than 95% by the FACSVantage SE (BD Biosciences). 
Western Blot

NF-B Reporter Assay
HEK293 cells expressing mTLR4/MD2-CD14 (Invivogen) were seeded at 4.0 ! 10 4 cells/well in 96-well plate and transfected with 200 ng of the reporter plasmid pNiFty2SEAP which encodes NF-B-inducible soluble form of embryonic alkaline phosphatase (AP) with 120 ng of either mCD22-pcDNA3.1(+) or empty vector. After 24 h incubation, 10 g/ml of LPS were added to wells. After 16 h incubation, AP activity in the supernatant was measured following the manufacturer's instruction.
NF-B DNA Binding Assay Nuclear extracts of Cd22
-/-and WT B cells were prepared using the Nuclear Extract Kit (Active Motif, Carlsbad, Calif., USA) following the manufacturer's instructions. Protein concentration was determined by BCA assay (Pierce) and 9.4 g of nuclear extracts per well were subjected to ELISA using oligonucleotides containing the NF-B-binding site and specific antibodies to determine which NF-B subunits within the bound complexes were active (TransAM NF-B Family Kit; Active Motif). Assays were run in triplicates.
Results and Discussion
Although CD22 is known as a regulator of the BCR, several earlier reports showed that B cells from Cd22 -/-mice exhibit hyperproliferation in response to LPS, a ligand of TLR4 [15] [16] [17] , and more recently to ligands to TLR7 and TLR9 [18] , which are localized to endosomes. However, the significance of these findings has been largely overlooked [1, 2] . CD22 is known to undergo constitutive endocytosis [19] , and is therefore localized to both the cell surface and endosomes, consistent with a potential role in regulation of these TLRs. As shown in figure 1 , CFSE-labeled B cells from Cd22 -/-mice exhibited hyperproliferation relative to WT B cells in response to ligands for TLRs 3, 4 and 9 (poly(I:C), LPS and CpG, respectively). Paradoxically, Cd22 -/-B cells showed slightly impaired proliferation in response to anti-IgM, consistent with several previous reports [15] [16] [17] . Proliferation by LPS and CpG was completely MyD88 dependent, consistent with known dependence on MyD88 for signaling mediated by TLR4 and TLR9 ( fig. 1 b) [20] , while signaling in response to poly(I:C) was unaffected by the MyD88 deficiency, since TLR3 mediates signaling through the TRIF pathway [20] . The CFSE dilution was concomitant with an increase in the absolute number of living Cd22 -/-B cells at 3 days culture ( fig. 1 c) . The augmented proliferation of Cd22 -/-B cells was accompanied by increased induction of the co-stimulatory molecule CD86 and MHC class II, required for activation of T cells ( fig. 2 ) . The augmented TLRs 3, 4 and 9 signaling in Cd22 -/-B cells was not a result of increased expression of TLRs, since expression of TLR3 and 9 in Cd22 -/-B cells was similar to that in WT B cells, and Cd22 -/-B cells express TLR4 at a lower level than WT B cells ( fig. 3 ; online suppl. fig. 1 , www.karger.com/doi/10.1159/000322375). Taken together, these data indicate that CD22 deficiency affects both MyD88-dependent and MyD88-independent TLR signaling in B cells.
Several approaches were taken to investigate the possibility that the increased TLR signaling might be an indirect effect of CD22 on B cell development. We first examined the impact of the expression of CD22 on TLR 
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signaling in the Cd22 -/-J2-44 B cell line [21] . MHC class II induction by TLR ligands was reproducibly suppressed by expression of CD22 ( fig. 4 a; online suppl. fig. 2 ), consistent with a direct effect of CD22 on TLR signaling. We next sought to demonstrate the impact of CD22 on TLR signaling on WT B cells by antibody-mediated sequestration of CD22, an approach used to demonstrate the importance of CD22 co-localization on the regulation of BCR signaling [22] . In wells containing immobilized anti-CD22 mAb, WT B cells exhibited enhanced proliferation in response to TLR ligands relative to cells exposed to wells with immobilized isotype control Ab ( fig. 4 online suppl. fig. 3 ), suggesting sequestration of CD22 from TLRs 4 and 9 by the immobilized anti-CD22 mAb augments proliferation by TLR ligands. Furthermore, using a TLR4 reporter cell line, we found that the transcriptional activity of NF-B, which is a hallmark of TLR signaling [20] , is well suppressed by the ectopic expression of CD22 in TLR4 reporter cells ( fig. 4 c; online suppl. fig. 4 ), suggesting that CD22 has an intrinsic inhibitory effect on NF-B activation. Thus, three independent approaches suggest that CD22 directly regulates TLR signaling in B cells. To gain further insight into the mechanism of negative regulation of TLR signaling by CD22, we tested whether hallmarks of TLR signaling pathways including p38, JNK and NF-B signaling were augmented in Cd22 -/-B cells. We found that p38 and JNK phosphorylation was similar in Cd22 -/-and WT B cells (online suppl. fig. 5 ). While the I B ␣ degradation which results in the release of NF-B dimers into nucleus, preferably p65/p50, is not altered in Cd22 -/-B cells (online suppl. fig. 4 ), we found that the repertoire of active NF-B subunits in Cd22 -/-B cells in both resting and CpG-stimulated conditions was significantly biased to the nonclassical NF-B pathways revealed by higher DNA-binding activity of p50, p52 and RelB than that in WT B cells ( fig. 5 a) [23] . With respect to inhibitory regulators of TLR activation, we found that induction of SOCS1 and 3, known as suppressors of TLR signaling [12] [13] [14] , was impaired in Cd22 -/-B cells ( fig. 5 b) . It is interesting to speculate that altered NF-B activation caused by CD22 deficiency results in poor induction of SOCS1 and 3, leading to the prolonged TLR signaling, which in turn results in the augmented phenotype of Cd22 -/-B cells. Our results suggest that CD22 is a constitutive negative regulator of TLR-activated signaling pathways that are distinct from and not mediated by the BCR [7] . Recently, Jellusova et al. [18] also reported the augmented proliferation of Cd22 -/-and Siglecg -/-B cells in response to TLR ligand. Results presented here suggest that the augmented TLR signaling in Cd22 -/-B cells is a consequence of the loss of constitutive negative regulation of TLR signaling by CD22 in B cells. This conclusion is relevant to the observation that mice carrying a TLR7 gene duplication (Y-linked autoimmune accelerator) exhibit an anti-DNA antibody autoimmune phenotype when crossed into a Cd22 +/-background [24] . Our data document that CD22 is a regulator of receptors that mediate both adaptive and innate immune responses of the B cell. In its regulation of the BCR, CD22 is believed to exert its activity through close physical association [3, 4, 25] . Since sequestration of CD22 augmented LPS activation of TLR4 signaling, this is also likely the case for CD22 regulation of TLRs. In this regard, since TLRs are located on both the cell surface (TLR4) and endosomal compartments (TLR3 and 9), CD22 regulation of TLRs might be tied to its constitutive endocytic activity, placing it both on the cell surface and in endosomal compartments [19, 26] .
CD22 is a member of the Siglec family, which comprises 14 human and 9 murine members that are predominantly expressed on leukocytes that mediate the adaptive and innate arms of immune function [1] . A few reports suggest that other Siglecs might regulate TLRs. Recently Siglec-E and H were found to regulate cytokine production in response to TLR ligand in macrophages and plasmacytoid dendritic cells, respectively [27, 28] . Similarly, ectopic expression of Siglec-9, 11 and 14 in macrophages has also been observed to influence cytokine production in response to TLR ligands [29] [30] [31] . Thus as shown here for CD22, it is likely that other Siglecs will be found to regulate TLR signaling in the cells that express them, and that this will prove to be a general property of the Siglec family. reagents and insightful discussions, the flow cytometry core facility in The Scripps Research Institute for cell sorting, and Anna Tran-Crie for her help in manuscript preparation. C.R. was supported by an EMBO long-term fellowship. This work was supported by NIH grant AI050143 to J.C.P.
